BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...

Lead program advancing to IND filing in H1 2025 for the treatment of X-linked chronic granulomatous disease (X-CGD) will be first in vivo HSC-directed therapy tested in humans Preclinical data to be ...

Remodeled the cold solid tumor microenvironment, marked by macrophage M1 polarization, increased lymphocyte recruitment, and production of inflammatory cytokines and chemokines.

On Tuesday, September 10, the UAB School of Engineering hosted an event to connect students, employers...and a handful of robots at the Engineering Fall Kickoff and Career Fair. UAB Engineering has ...